INFECTIOUS AGENTS, VACCINES & ANTIMICROBIALS IN HUMANS

传染源、疫苗

• 批准号: 3725835
• 负责人: MARY LOU CLEMENTS
• 金额: $ 128.95万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-12-01 至 1995-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3725835
• 关键词: Pneumovirus; adult human (21+); antiviral agents; biomedical facility; child (0-11); clinical trials; gastrointestinal infection; immunological substance; live vaccine; microorganism immunology; respiratory infections; virulence; virus diseases

The main aim of the LID is to understand the pathogenesis of important respiratory and enteric viral pathogens of humans and to develop means to prevent illness caused by these viruses. The purpose of the new contract is to provide volunteers and a facility in which to study the biology of medically important viruses in humans, to examine the hosts immune response to these viruses, and to test new candidate live virus vaccines for safety, genetic stability, immunogenecity, transmissibility and protective efficacy. Studies will also include administration of wild type viruses to volunteers in order to assess virulence. Subsequently, these wild type viruses will be used to challenge vaccinated volunteers in order to assess the extent of immunity induced by candidate vaccines. Studies with vaccines will include an evaluation of their safety, immunogenecity, transmissibility, and protective efficacy. These studies will include both adult and pediatric subjects since the viruses studied cause disease in both these populations; e.g., influenza A viruses cause severe respiratory disease in the elderly and, conversely, respiratory syncytial virus causes severe respiratory disease in infants. In summary, the new contract facility will provide facilities and populations to study the biology and immunology of a variety of viral pathogens and will serve as a testing center for the development of new vaccines effective against these agents.

LID 的主要目的是了解重要疾病的发病机制 人类呼吸道和肠道病毒病原体，并开发方法 预防由这些病毒引起的疾病。 新合同的目的 是提供志愿者和研究生物学的设施 人类医学上重要的病毒，用于检查宿主的免疫反应 针对这些病毒，并测试新的候选活病毒疫苗的安全性， 遗传稳定性、免疫原性、传播性和保护性 功效。 研究还将包括使用野生型病毒 志愿者以评估毒力。 随后，这些野生型 病毒将用于挑战接种疫苗的志愿者，以评估 候选疫苗诱导的免疫程度。 研究与 疫苗将包括对其安全性、免疫原性的评估， 传播性和保护功效。 这些研究将包括成人和儿童受试者，因为 研究的病毒会在这两个人群中引起疾病​​；例如甲型流感 病毒会导致老年人出现严重的呼吸道疾病，相反， 呼吸道合胞病毒会导致婴儿严重的呼吸道疾病。 总之，新合同设施将提供设施和 研究多种病毒的生物学和免疫学 病原体，并将作为开发新病原体的测试中心 对这些病原体有效的疫苗。